Airway diseases – such as chronic obstructive pulmonary disease and obstructive sleep apnoea – have a significant impact on one’s health, quality of life and daily functioning. This article discusses how technological advancements in non-invasive ventilation and home sleep testing systems help to improve patient care and outcomes.
Literature suggests that IPF is either the first or second most common interstitial lung disease (ILD) in pulmonology practice, with prevalence ranging from 17–86%. At the recent 3rd Respiratory Forum organized by Boehringer Ingelheim, Dr Felix Chua shared his insights into the importance of advancing the treatment paradigm of IPF, and the role of nintedanib (OFEV®) in its management.
The prevalence of allergic diseases in the Asia-Pacific region is expected to rise over the next 20 years, driven by rapid economic development and urbanization. Allergic diseases have high socioeconomic impact by impairing productivity and quality of life, and the impact may be greater in Asia-Pacific than in Europe due to the presence and predominance of perennial allergens.
At a GlaxoSmithKline-sponsored symposium during the Malaysian Thoracic Society Annual Congress 2017, Dr Celeste Mae Lardizabal-Campomanes presented on three key strategies of optimizing asthma treatment.
At the Malaysian Thoracic Society Annual Scientific Congress 2017 held recently in Kuala Lumpur, Associate Professor Pang spoke on the importance of influenza vaccination in patients with chronic respiratory diseases and lung cancer, highlighting the benefit of quadrivalent influenza vaccines (QIVs) in providing a wider spectrum of protection against influenza types A and B.
Persistent pulmonary hypertension of the newborn (PPHN) is a common phenomenon in infants with moderate or severe hypoxic ischaemic encephalopathy (HIE), a recent study has shown. Moreover, PPHN is linked to lung disease, sepsis and increased mortality.
Fluticasone furoate is superior to mometasone nasal spray in improving several perceived sensory attributes of allergic rhinitis patients, based on a multicentre, randomised, crossover, prospective study.